Biomarker studies should also be integrated to help identify which patients are most likely to benefit from this combined modality—for example, evaluating tumor PD-L1 expression, immune cell infiltration in the tumor microenvironment, or specific genetic markers. Here, CD274 is linked to neoplasm.